Price (delayed)
$1.19
Market cap
$60.38M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.34
Enterprise value
-$87.98M
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, ...
Highlights
CABA's net income has dropped by 71% year-on-year and by 11% since the previous quarter
Cabaletta Bio's quick ratio has shrunk by 60% YoY and by 24% QoQ
Key stats
What are the main financial stats of CABA
MarketValuationsEarnings
Shares outstanding
50.74M
Market cap
$60.38M
Enterprise value
-$87.98M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.38
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$125.14M
Net income
-$115.86M
EBIT
-$115.12M
EBITDA
-$110.57M
Free cash flow
-$90.43M
Per shareBalance sheetLiquidity
EPS
-$2.34
EPS diluted
-$2.34
Free cash flow per share
-$1.85
Book value per share
$3.12
Revenue per share
$0
TBVPS
$3.79
Total assets
$185.05M
Total liabilities
$32.71M
Debt
$15.6M
Equity
$152.34M
Working capital
$139.59M
Debt to equity
0.1
Current ratio
6.15
Quick ratio
6.05
Net debt/EBITDA
1.34
MarginsEfficiencyDividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-54.7%
Return on equity
-62%
Return on invested capital
-385.6%
Return on capital employed
-72.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CABA stock price
How has the Cabaletta Bio stock price performed over time
Intraday
-4.03%
1 week
-26.09%
1 month
-28.74%
1 year
-92.76%
YTD
-47.58%
QTD
-14.08%
Financial performance
How have Cabaletta Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$125.14M
Net income
-$115.86M
Gross margin
N/A
Net margin
N/A
CABA financials
CABA's net income has dropped by 71% year-on-year and by 11% since the previous quarter
The operating income has plunged by 68% YoY and by 9% from the previous quarter
Growth
What is Cabaletta Bio's growth rate over time
CABA growth chart
Valuation
What is Cabaletta Bio stock price valuation
P/E
N/A
P/B
0.38
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Price to earnings (P/E)
CABA's EPS is down by 42% YoY and by 8% QoQ
Price to book (P/B)
CABA's price to book (P/B) is 82% lower than its 5-year quarterly average of 2.1 and 80% lower than its last 4 quarters average of 1.9
The equity has contracted by 36% YoY and by 13% from the previous quarter
Price to sales (P/S)
Efficiency
How efficient is Cabaletta Bio business performance
The ROIC has plunged by 125% YoY and by 47% from the previous quarter
Cabaletta Bio's ROE has plunged by 52% YoY and by 24% from the previous quarter
Cabaletta Bio's return on assets has decreased by 44% YoY and by 20% QoQ
Dividends
What is CABA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CABA.
Financial health
How did Cabaletta Bio financials performed over time
Assets vs liabilities
Cabaletta Bio's total liabilities has soared by 87% YoY and by 8% from the previous quarter
The current ratio has plunged by 60% YoY and by 24% from the previous quarter
Debt vs equity
CABA's debt is 90% smaller than its equity
The equity has contracted by 36% YoY and by 13% from the previous quarter
Cabaletta Bio's debt to equity has increased by 11% from the previous quarter
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from 
and Sharadar.